<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023020</url>
  </required_header>
  <id_info>
    <org_study_id>ECRI-009</org_study_id>
    <nct_id>NCT03023020</nct_id>
  </id_info>
  <brief_title>Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen</brief_title>
  <acronym>MASTER DAPT</acronym>
  <official_title>Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECRI bv</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardialysis B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Terumo Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ECRI bv</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares two lengths of medication therapy (a shortened versus a prolonged dual
      antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the
      successfully treatment for coronary heart disease with a drug covered stent (metallic tube).

      This comparison will be done in patients who, compared to the average patient, are more
      likely to suffer from complications on antiplatelet therapy (bleeding). Both durations are
      within the current medical recommendations. The aim of this study is to help improve further
      standard antiplatelet duration guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to determine in a high bleeding risk patient population undergoing PCI
      under standardized treatment (within current guidelines and instructions for use and
      including the bioresorbable polymer coated Ultimaster sirolimus-eluting stent), whether
      abbreviated DAPT is non-inferior to prolonged DAPT regimen in terms of NACE within 12 months,
      whether abbreviated DAPT is non-inferior to prolonged DAPT regimen in terms of MACCE within
      12 months and whether abbreviated DAPT is superior to prolonged DAPT regimen in terms of MCB
      within 12 months.

      There are two treatment strategies:

        -  abbreviated dual anti-platelet therapy: dual antiplatelet therapy is discontinued and a
           single antiplatelet agent is continued until at least 11 months post randomization (i.e.
           12 months post stent implantation). In patients on oral anticoagulants, dual
           antiplatelet therapy is discontinued and either Aspirin or Clopidogrel is continued
           until 5 months post randomization (i.e. 6 months post stent implantation). Oral
           anticoagulation is continued until at least 11 months post randomization (i.e. 12 months
           post stent implantation) OR

        -  prolonged dual anti-platelet therapy: aspirin is continued for at least 11 months post
           randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken
           at the time of randomization is continued for at least 5 months and up to 11 months post
           randomization (i.e. 12 months post stent implantation). In patients on oral
           anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post
           randomization (i.e. 3 months post stent implantation) and up to 11 months post
           randomization (i.e. 12 months after stent implantation). Therefore either aspirin or
           Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent
           implantation)

      The study design is an investigator-initiated, randomized, multi-center, clinical trial to be
      conducted in approximately 100 interventional cardiology centers in across the globe
      excluding USA. The study includes 2 x 2150 patients (i.e. 4300 patients) Randomization will
      occur at one month after the PCI procedure. The expected duration of participation for each
      patient is 14 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net adverse clinical endpoints (NACE) defined as a composite of all-cause death, myocardial infarction, stroke and bleeding events defined as BARC 3 or 5</measure>
    <time_frame>11 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiac and cerebral events (MACCE) defined as a composite of all-cause death, myocardial infarction and stroke</measure>
    <time_frame>11 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major or clinically relevant non-major bleeding (MCB) defined as a composite of type 2, 3 and 5 BARC bleeding events</measure>
    <time_frame>11 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from cardiovascular causes</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite or probable stent thrombosis</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any target vessel revascularization</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent target vessel revascularization</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent non-target vessel revascularization</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated non-target vessel revascularization</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion rates both in patients with and/or without clinically detected over bleeding</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4300</enrollment>
  <condition>High Bleeding Risk</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>PCI</condition>
  <arm_group>
    <arm_group_label>Abbreviated antiplatelet regimen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation).
In patients on oral anticoagulants, dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prolonged antiplatelet regimen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation).
In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Dosing per current guidelines and local practice</description>
    <arm_group_label>Abbreviated antiplatelet regimen</arm_group_label>
    <arm_group_label>Prolonged antiplatelet regimen</arm_group_label>
    <other_name>antiplatelet agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P2Y12 inhibitor</intervention_name>
    <description>Dosing per current guidelines and local practice</description>
    <arm_group_label>Abbreviated antiplatelet regimen</arm_group_label>
    <arm_group_label>Prolonged antiplatelet regimen</arm_group_label>
    <other_name>antiplatelet agent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        After index PCI, patients aged 18 years or more are eligible for inclusion into the study
        if the following criteria are met.

          1. At least one among the HBR criteria (as defined below) is met.

          2. All lesions are successfully treated with Ultimaster stent in the context of routine
             clinical care, i.e. post-procedural angiographic diameter stenosis &lt;20% by visual
             estimation

          3. Free from any flow-limiting angiographic complications (i.e. significant untreated
             dissection or major side-branch occlusion), which require prolonged DAPT duration
             based on operator's opinion.

          4. All stages of PCI are complete (if any) and no further PCI is planned.

        At randomization visit (one month after index PCI), the following criteria must be met:

          1. Fulfilment of at least one HBR criterion (as defined below), or on the basis of
             post-PCI actionable (i.e. requiring medical attention) non-access site related
             bleeding episode

          2. Uneventful 30-day clinical course, i.e. free from spontaneous MI, symptomatic
             restenosis, stent thrombosis, stroke and any revascularization (coronary and
             non-coronary) requiring prolonged DAPT

          3. If not on OAC,

               1. Patient is on a DAPT regimen of aspirin and a P2Y12 inhibitor

               2. Patient with one type of P2Y12 inhibitor for at least 7 days (i.e. no switching
                  between oral P2Y12 inhibitors has occurred in the previous 7 days)

          4. If on OAC

               1. Patient is on the same type of OAC (e.g. Vitamin K antagonist or NOAC) for at
                  least 7 days

               2. Patient is on clopidogrel for at least 7 days

        Definition of HBR

        Post-PCI patients are at HBR if at least one of the following criteria applies:

          -  Clinical indication for treatment with oral anticoagulants (OAC) for at least 12
             months

          -  Recent (&lt;12 months) non-access site bleeding episode(s), which required medical
             attention (i.e. actionable bleeding).

          -  Previous bleeding episode(s) which required hospitalization if the underlying cause
             has not been definitively treated (i.e. surgical removal of the bleeding source)

          -  Age equal or greater than 75 years

          -  Systemic conditions associated with an increased bleeding risk (e.g. haematological
             disorders, including a history of or current thrombocytopaenia defined as a platelet
             count &lt;100,000/mm3 (&lt;100 x 109/L), or any known coagulation disorder associated with
             increased bleeding risk.

          -  Documented anaemia defined as repeated haemoglobin levels &lt;11 g/dl or transfusion
             within 4 weeks before randomization.

          -  Need for chronic treatment with steroids or non-steroidal anti-inflammatory drugs

          -  Diagnosed malignancy (other than skin) considered at high bleeding risk including
             gastro-intestinal, genito-urethral/renal and pulmonary.

          -  Stroke at any time or TIA in the previous 6 months

          -  PRECISE DAPT score of 25 or greater

        Exclusion Criteria:

          1. Treated with stents other than Ultimaster stent within 6 months prior to index
             procedure

          2. Treated for in-stent restenosis or stent thrombosis at index PCI or within 6 months
             before

          3. Treated with a bioresorbable scaffold at any time prior to index procedure

          4. Cannot provide written informed consent

          5. Under judicial protection, tutorship or curatorship

          6. Unable to understand and follow study-related instructions or unable to comply with
             study protocol

          7. Active bleeding requiring medical attention (BARC≥2) on randomization visit

          8. Life expectancy less than one year

          9. Known hypersensitivity or allergy for aspirin, clopidogrel, ticagrelor, prasugrel,
             cobalt chromium or sirolimus

         10. Any planned and anticipated PCI

         11. Participation in another trial

         12. Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Valgimigli, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital Universitätsspital Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. Smits, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maasstad Ziekenhuis Rotterdam, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GA Van Es</last_name>
    <role>Study Director</role>
    <affiliation>ECRI bv</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GA Van Es</last_name>
    <phone>+31102062828</phone>
    <email>GA.vEs@ecri-trials.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Centre Manama</name>
      <address>
        <city>Manama</city>
        <country>Bahrain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center Hasselt</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHAT Sveta Karidad Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Heart Hospital</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center Tallinn</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Prive Saint Martin</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Créteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GCIDB-Hospital Prive Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center Massy</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Mercy</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique du Pont de Charme</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Prive le Confluent</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Europeen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cetre Cardiologique du Nord</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Invasive Cardiology Unit University of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>G Kuppuswamy Naida Memorial Hospital</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin MC</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center Seoul</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center Skopje</name>
      <address>
        <city>Skopje</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Arnhem</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Dordrecht</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center Emmen</name>
      <address>
        <city>Emmen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Enschede</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Terneuzen</name>
      <address>
        <city>Terneuzen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Wroclaw</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center Riyadh</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lindenhofspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Fribourg</name>
      <address>
        <city>Fribourg</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Liestal</name>
      <address>
        <city>Liestal</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Lugano</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Brighton</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lee Haynes Research Institute</name>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Stoke-on-Trent</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Wolverhampton</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centre Worcester</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bahrain</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29.</citation>
    <PMID>25173339</PMID>
  </reference>
  <reference>
    <citation>Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group . 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.</citation>
    <PMID>26320110</PMID>
  </reference>
  <reference>
    <citation>Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC, Jr. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016</citation>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dual Antiplatelet Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

